Recent 8-K filings for ATXI

• Feb 23, 2026 23:59 UTC other_material materiality 0.65 positive item 1.01item 8.01item 9.01

  Avenue Therapeutics licenses ATX-04 from Duke University for Pompe disease; plans late-stage development

  Exclusive worldwide license from Duke for ATX-04 (clenbuterol) to treat Pompe disease as adjunct to ERT.

• Nov 12, 2025 23:59 UTC m_and_a materiality 0.75 positive item 1.01item 5.02item 8.01item 9.01

  Avenue Therapeutics' subsidiary Baergic Bio acquired by Axsome for up to $82M milestones plus royalties

  Axsome acquires 100% of Baergic Bio equity for $0.3M upfront; development/regulatory milestones up to $2.5M (first indication) and $1.5M per subsequent indication.

• Apr 30, 2025 23:59 UTC other_material materiality 0.85 negative item 1.01item 1.02item 2.01item 9.01

  Avenue Therapeutics terminates AJ201 license; gets $2M cash, up to $24M milestones, 1.75% royalty

  License terminated; all AJ201 rights and assets transferred back to AnnJi; mutual releases and dismissal of disputes.

• Mar 17, 2025 23:59 UTC regulatory materiality 0.90 negative item 3.01

  Nasdaq to delist Avenue Therapeutics on March 19; stock to trade on OTC Markets

  Nasdaq notified Company it will delist common stock effective at open on March 19, 2025.

• Mar 07, 2025 23:59 UTC other_material materiality 0.80 negative item 8.01item 9.01

  Nasdaq grants Avenue Therapeutics continued listing exception; AnnJi seeks to terminate AJ201 license

  Nasdaq Panel granted continued listing subject to: public disclosure by Mar 14, fundraising update by Mar 14, AJ201 trial results by Apr 15.

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event other_material

2 positive 3 negative 2 neutral

source · ATXI on sec.gov